Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis
| Autor: | Adela Gallego Flores, Aurora Herrero Olea, Estíbaliz Loza Santamaría, María Piedad Rosario Lozano, Eugenio Chamizo Carmona |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Bone Density Conservation Agents Diphosphonates business.industry Incidence Osteoporosis General Medicine medicine.disease Evidence level Risk Assessment Clinical trial Systematic review Treatment Outcome Internal medicine Text messaging medicine Humans In patient Bisphosphonate-Associated Osteonecrosis of the Jaw Significant risk Osteonecrosis of the jaw business |
| Zdroj: | Reumatologia clinica. 9(3) |
| ISSN: | 1885-1398 |
| Popis: | Objective To systematically assess the literature related to the occurrence of osteonecrosis of the jaw (ONJ) using bisphosphonates (BP) in the treatment of osteoporosis (OP). Methods We conducted a systematic literature search in PubMed, EMBASE and the Cochrane Central Register of Controlled Trials up to July 2010, including terms relating to OP, ONJ, and BP (MeSH and free text). We selected meta-analysis, systematic reviews (SRs) and clinical trials (CTs), English or Spanish, including patients >18 years of both sexes with OP treated with BP (intravenous and oral). Furthermore, studies should evaluate the occurrence of ONJ during treatment with BP. We excluded studies that included patients with cancer or diseases other than OP, animal studies and basic science. The selection of articles both by title and 2 independent reviewers conducted a detailed review of the abstracts. We used the modified Oxford Scale (version 2001) to assess the quality of the included studies. Results We identified 1422 articles of which we included 18 (8 SRs, 8 CT and 2 meta-analysis). Most studies were of good quality and examined the use of BP in middle-aged women with OP. Frequency of ONJ was low. Conclusions We found insufficient evidence to affirm that intravenous or oral BP used exclusively for the treatment of OP lead to a significant risk of ONJ (evidence level 2a, grade B recommendation). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|